What is the recommended dosing for Linzess (linaclotide) in adults with IBS‑C or chronic idiopathic constipation, and how should the dose be adjusted in renal impairment?

Linzess (Linaclotide) Dosing

For adults with IBS-C, use 290 mcg once daily; for chronic idiopathic constipation, use 145 mcg once daily (or 72 mcg if needed for tolerability); for pediatric functional constipation (ages 6-17), use 72 mcg once daily—all taken on an empty stomach at least 30 minutes before the first meal. 1

FDA-Approved Dosing by Indication

Adults with IBS-C

• 290 mcg orally once daily is the recommended dose 1
• This higher dose has been shown to improve both bowel symptoms (constipation) and abdominal symptoms (pain, bloating, discomfort) in IBS-C patients 2, 3

Adults with Chronic Idiopathic Constipation (CIC)

• 145 mcg orally once daily is the standard recommended dose 1
• 72 mcg orally once daily may be used based on individual presentation or tolerability 1
• The 72 mcg dose was FDA-approved after demonstrating significant efficacy with lower rates of diarrhea-related discontinuation (2.4% vs 3.2% for 145 mcg) 4
• Both the 72 mcg and 145 mcg doses are listed as options in the 2023 AGA-ACG guidelines, with a maximum dose of 290 mcg daily 2

Pediatric Patients (Ages 6-17) with Functional Constipation

• 72 mcg orally once daily 1

Critical Administration Instructions

Timing Relative to Meals

• Take on an empty stomach at least 30 minutes prior to the first meal of the day 1
• This timing is essential: taking linaclotide immediately after a high-fat breakfast produces looser stools and higher stool frequency compared to fasting administration 5
• Administer at approximately the same time each day for consistency 1

Capsule Handling

• Swallow capsules whole; do not crush or chew 1
• For patients unable to swallow capsules, the capsule may be opened and contents administered with applesauce or water, or via nasogastric/gastrostomy tube 1

Missed Dose Protocol

• If a dose is missed, skip it and take the next dose at the regular time 1
• Never take 2 doses at the same time 1

Dose Adjustment Considerations

Renal Impairment

• No dose adjustment is required 5
• Linaclotide has minimal systemic absorption; plasma concentrations are below the limit of quantitation after oral doses of 72 mcg, 145 mcg, or 290 mcg 5
• Because systemic exposure is negligible, renal impairment does not necessitate dose modification 5

Hepatic Impairment

• No dose adjustment is required for linaclotide 5
• Note: This contrasts with lubiprostone (a different constipation agent), which does require dose reduction in moderate-to-severe hepatic insufficiency 5

Elderly Patients (≥65 Years)

• Use the same doses as younger adults; no age-based modification is needed 5
• In pivotal CIC trials, 11% of participants were ≥65 years and 2% were ≥75 years, with efficacy and safety outcomes comparable to younger patients 5
• In IBS-C trials, 7% were ≥65 years with similar clinical response rates 5
• Monitor closely for diarrhea during the first three months, as this is when most episodes occur (16-20% overall incidence) 5, 6

Common Pitfalls and Management Strategies

Diarrhea Management

• Diarrhea is the most common adverse event, occurring in 16-20% of patients 2, 7, 6
• Most diarrhea is mild to moderate (90.5% in clinical trials) and occurs within the first three months of therapy 5, 6
• Discontinuation due to diarrhea is relatively uncommon: 4.0% in randomized trials vs 0.3% for placebo 6
• If diarrhea occurs, consider dose reduction (e.g., from 145 mcg to 72 mcg in CIC patients) or temporary discontinuation 8
• Patients should be warned about this risk before starting therapy and given clear instructions on how to manage it 9

Duration of Therapy

• Linaclotide should be taken continuously, not sporadically 9
• There is no evidence of tachyphylaxis, so treatment can be maintained for long periods 9
• In long-term safety studies extending up to 104 weeks, the safety profile remained favorable 6

Pre-Procedure Considerations

• Discontinue linaclotide 48-72 hours (2-3 days) before gastric emptying scintigraphy to avoid confounding results from accelerated colonic transit and potential diarrhea 10
• Resume therapy promptly after the procedure 10

Contraindications

• Absolutely contraindicated in patients less than 2 years of age due to risk of serious dehydration and death (demonstrated in neonatal mice studies) 1
• Contraindicated in patients with known or suspected mechanical gastrointestinal obstruction 2

Mechanism Supporting Dosing Strategy

• Linaclotide is a guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates gastrointestinal transit, with primary effects on the colon 2, 11, 7
• The drug acts locally in the GI tract with minimal systemic absorption, resulting in low oral bioavailability and minimal risk of systemic adverse effects 11, 7
• The dual mechanism—both secretory and analgesic (via reduction of visceral hypersensitivity)—explains why the higher 290 mcg dose is used for IBS-C, where abdominal pain is a cardinal feature 2, 11, 12